Studies by phase
Phase 1/2 studies appear in both phase counts.
Find studies by therapy or target
Explore therapies and registered intervention names linked to active myeloma studies. Counts include all study arms, including background treatment and comparators.
Active study counts
The phase chart and target counts describe active interventional studies. A study may report multiple phases or include several targets.
Studies by target family
Each study counts once per target family. Families overlap and do not form shares of a total.
91 therapy and intervention entities with active studies. Aliases are merged where a reviewed mapping exists; remaining names can include regimens or dose variants and are not a count of distinct development programs.
Phase 4
Dexamethasone
Corticosteroid · Glucocorticoid receptor
Highest phase among linked studies; not an approval status.
225active studies90recruiting
Phase 4
Lenalidomide
IMiD · Cereblon
Highest phase among linked studies; not an approval status.
148active studies54recruiting
Phase 4
Daratumumab
Monoclonal antibody · CD38
Highest phase among linked studies; not an approval status.
146active studies65recruiting
Phase 4
Bortezomib
Proteasome inhibitor · Proteasome
Highest phase among linked studies; not an approval status.
97active studies34recruiting
Phase 4
Pomalidomide
IMiD · Cereblon
Highest phase among linked studies; not an approval status.
87active studies38recruiting
Phase 4
Carfilzomib
Proteasome inhibitor · Proteasome
Highest phase among linked studies; not an approval status.
71active studies24recruiting
Phase 4
Isatuximab
Monoclonal antibody · CD38
Highest phase among linked studies; not an approval status.
56active studies22recruiting
Phase 4
Cyclophosphamide
Chemotherapy · DNA alkylation
Highest phase among linked studies; not an approval status.
55active studies30recruiting
Phase 4
Teclistamab
Bispecific antibody · BCMA × CD3
Highest phase among linked studies; not an approval status.
46active studies23recruiting
Lead sponsors
Active studies grouped by their registered lead sponsor. These counts describe trial attribution, not medicine ownership or market share.
Industry sponsors
Registry industry classification
- 0133activeJanssen Research & Development, LLC
- 0220activeGlaxoSmithKline
- 0317activeAbbVie
- 0412activeRegeneron Pharmaceuticals
- 058activePfizer
- 068activeSanofi
- 077activeAstraZeneca
- 086activeCelgene
Government, academic and other sponsors
Registry non-industry classification
- 0146activeNational Cancer Institute (NCI)
- 0238activeInstitute of Hematology & Blood Diseases Hospital, China
- 0332activeMemorial Sloan Kettering Cancer Center
- 0417activeM.D. Anderson Cancer Center
- 0515activeMayo Clinic
- 0612activePETHEMA Foundation
- 0712activeMassachusetts General Hospital
- 0811activeWashington University School of Medicine
Studies are included by the documented disease query. Classification coverage is limited to reviewed aliases and target rules. An active study may be evaluating supportive care, diagnostics or a comparator rather than a new myeloma therapy.